Axitinib-13C,d3

• CAS Number:

  1261432-00-1

• UNSPSC Description:

  Axitinib-13C,d3 is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

• Target Antigen:

  PDGFR; VEGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Purity:

  97.80

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H][13C]([2H])([2H])NC(C(C=CC=C1)=C1SC2=CC=C3C(/C=C/C4=CC=CC=N4)=NNC3=C2)=O

• Molecular Weight:

  390.48

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Fenton BM, et al. The addition of AG-013736 to rractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67(20):9921-8.;Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272-83;Allen E, et al. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep. 2016 May 10;15(6):1144-60.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C

• Clinical Information:

  No Development Reported